
| Pair Name | Escin, Cisplatin | ||
| Phytochemical Name | Escin (PubChem CID: 16211024 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Escin, Cisplatin | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Ferroptosis | |||
| Gene Regulation | Down-regulation | Expression | GPX4 | hsa2879 |
| Down-regulation | Expression | G6PD | hsa2539 | |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
| In Vivo Model | MDA-MB-231 cells (2.5×10⁶ cells per mouse) stably expressing sh-NC and sh-G6PD were established.When the tumor grew to approximately 60 mm3, 2 mg/kg Escin was intraperitoneally injected with normal saline as the control. | |||
| Result | Role of Escin in breast cancer therapy: potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin | |||
| No. | Title | Href |
|---|---|---|
| 1 | Role of Escin in breast cancer therapy: potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin. Apoptosis. 2023 Aug;28(7-8):1154-1167. doi: 10.1007/s10495-023-01849-x. | Click |